Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343
78278343PCR3001
Phase 3 small_molecule active
Quick answer
Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343 for Metastatic Castration-resistant Prostate Cancer (mCRPC) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active